Selenium supplement for people with heart failure
Tests daily selenium against placebo in adults with heart failure.
Plain-language title generated from the registry record
Registry title: Selenium Intervention Registry Randomized Trial in Heart Failure
Key facts
- Where
- Gothenburg, Jönköping, Linköping, Lund, Malmö, Örebro, Stockholm, Umeå, and Uppsala, SwedenSee the 10 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure who were discharged from hospital with a heart failure diagnosis recorded in the SwedeHF registry. Half take selenium daily, half take a placebo.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Heart failure as the main diagnosis at hospital discharge (ICD-10: I50), recorded in the SwedeHF registry.
Main reasons for not taking part
- Severe or terminal other illness with a poor outlook, in the opinion of the investigator
- Pregnancy
- Anything that could get in the way of following the trial plan, in the investigator's opinion
Read by machine on 9 November 2026.
Where in Sweden
- SahlgrenskaGothenburg, SwedenTaking people
- Sahlgrenska University Hospital/ÖstraGothenburg, SwedenTaking people
- Ryhov HospitalJönköping, SwedenTaking people
- Linkoping University HospitalLinköping, SwedenTaking people
- Skånes University HospitalLund, SwedenTaking people
- Skånes University HospitalMalmö, SwedenTaking people
- Örebro University HospitalÖrebro, SwedenTaking people
- Karolinska University HospitalStockholm, SwedenTaking people
- Norrlands University HospitalUmeå, SwedenTaking people
- Akademiska University HospitalUppsala, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Skane University Hospital
- Trial code
- NCT07543562
- Record updated
- 22 April 2026
- Original description
Heart failure is a serious condition in which the heart is unable to pump blood effectively, and it remains a leading cause of hospitalization and death worldwide despite advances in treatment.Read full original descriptionShow less
Selenium Intervention Registry Randomized Trial in Heart Failure
Heart failure is a serious condition in which the heart is unable to pump blood effectively, and it remains a leading cause of hospitalization and death worldwide despite advances in treatment.
Selenium is an essential micronutrient that plays an important role in cellular energy production, antioxidant defense, and overall cardiovascular function. Low selenium levels are common among patients with heart failure in Northern Europe, and observational studies have shown that selenium deficiency is associated with an increased risk of hospitalization and death. In cases of severe deficiency, such as in Keshan disease, heart dysfunction can be reversed with selenium supplementation, suggesting a potential causal relationship.
However, it is not yet known whether selenium supplementation can improve clinical outcomes in patients with heart failure when added to standard medical therapy.
The SIRI-HF trial is a randomized, placebo-controlled study designed to evaluate whether daily supplementation with 200 micrograms of selenium, in addition to guideline-directed medical therapy, improves outcomes in patients with heart failure.
The primary endpoint is a composite of recurrent heart failure hospitalizations and cardiovascular death. Secondary endpoints include all-cause mortality, changes in symptoms and functional status, and safety outcomes.
This study will include patients from Sweden and Norway and aims to determine whether correcting selenium deficiency can improve prognosis in heart failure.
Inclusion: To be considered for inclusion in this study, patients must meet all of the following eligibility requirements:; 18 years of age; primary discharge diagnosis of HF coded as ICD-10: I50, as recorded in The SwedeHF registry; be able to provide documented informed consent by signing and dating the designated consent form.
Exclusion: Not suitable in the opinion of the Investigator (for example due to severe or terminal comorbidity with poor prognosis, or characteristics, pregnancy etc.) that may interfere with adherence to trial protocol.